Summary
BeOne Medicines Ltd. (ONC) has announced a significant development regarding its listing application on the STAR Market of the Shanghai Stock Exchange. The Listing Committee has reviewed and approved the application, with the results published on June 28, 2021. This approval is a crucial step towards the company's potential listing on the STAR Market, which could provide new avenues for capital raising and enhanced visibility within the Chinese market. However, investors should note that the consummation of this STAR Offering is contingent upon several factors, including favorable market conditions and obtaining additional regulatory approvals, specifically registration from the China Securities Regulatory Commission. The company explicitly warns that there is no assurance the offering will materialize or when it might occur. Shareholders and potential investors are advised to exercise caution when dealing in the company's securities, as the offering is subject to significant uncertainties.
Key Highlights
- 1BeOne Medicines Ltd.'s listing application for the STAR Market has been reviewed and approved by the Listing Committee.
- 2The approval signifies a key milestone towards a potential listing on the Shanghai Stock Exchange's STAR Market.
- 3The STAR Offering is subject to market conditions and further regulatory approvals, including registration with the China Securities Regulatory Commission.
- 4There is no guarantee that the STAR Offering will be completed or its timing.
- 5The company advises shareholders and potential investors to exercise caution regarding the securities.
- 6The announcement was made via an 8-K filing on June 28, 2021.